Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. operates within a growing market for ADHD medications, which has experienced approximately 8% annual growth since 2010, culminating in sales of nearly $18 billion in 2020. The company has reported positive topline results from its CTx-1301 trials, showing a beneficial effect compared to the placebo group, which bolsters confidence in the efficacy of its product pipeline. Given this positive trial data and the expanding market potential, there exists significant upside for Cingulate’s stock, reflecting a favorable outlook amidst high risks.

Bears say

Cingulate Inc reported a net loss of $4.8 million or an EPS of $(1.09), which was worse than both its estimates and consensus expectations, highlighting ongoing financial difficulties. Additionally, a significant net loss of $7.3 million or an EPS of $(1.35) further underscores inefficiencies, with projected estimates also falling short of expectations. The company faces multiple risks including liquidity issues, potential failure of its product candidates in clinical trials, and challenges in gaining regulatory approvals, which collectively contribute to a negative outlook on its stock performance.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.